Trastuzumab emtansine (T-DM1) is a standard treatment option in patients with previously treated human epidermal growth factor receptor 2–positive (HER2+) locally advanced or metastatic breast cancer (LA/MBC). Here, we report the efficacy and safety of tucatinib in combination with T-DM1 compared with T-DM1 alone from the phase III HER2CLIMB-02 study (NCT03975647).
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02
Annals of Oncology | | S.A. Hurvitz, S. Loi, J. O’Shaughnessy, A.F.C. Okines, S.M. Tolaney, J. Sohn, C. Saura, X. Zhu, D. Cameron, T. Bachelot, E. Hamilton, G. Curigliano, A.C. Wolff, N. Harbeck, N. Masuda, L. Vahdat, K. Zaman, F. Valdes-Albini, M. Block, T. Pluard, T.J. Tan, C. Gawryletz, A. Chan, P.L. Bedard, R. Yerushalmi, B. Xu, M. Schmitt, D. Xie, V.F. Borges, HER2CLIMB-02 study investigators
Topics: breast-cancer, blood-cancer, clinical-trials, research